FDA
-
-
-
-
-
-
-
Medicenna Announces the Launch of a Marketed Public Offering of Securities
-
-
-
-
-
-
-
Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
-
-
-
-
-
-
-
Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update
-
-
-
-
-
-
-
Medicenna to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
-
-
-
-
-
-
-
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeti
-
-
-
-
-
-
-
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the America
-
322,748 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

